GlobalLux RX is proud to share a major advancement in our oncology pipeline
Elacestrant has successfully achieved Fed Bioequivalence, marking a critical milestone toward a early submission readiness across key global markets.
This success solidifies Elacestrant position as a high-impact systemic option for ER+/HER2– breast cancer and strengthens our leadership in a high-barrier, rapidly expanding SERD landscape. As growing global demand highlights the therapy’s rising market potential, this BE milestone brings significant commercial and strategic value to prospective partners.
On track for an early submission, unlocking a uniquely competitive advantage in the evolving endocrine therapy market.
U.S. Out-Licensing Opportunity Now Open
We invite U.S. commercialization partners to access a differentiated, oncology asset backed by robust science, regulatory momentum, and strategic timing aligned for high-value market entry.
For partnership discussions, please contact:
Maxim Vlasenko
Lead BD & Strategy, GlobalLux RX
Contact maxim.vlasenko@globalluxrx.comElacestrant has successfully achieved Fed Bioequivalence, marking a critical milestone toward a early submission readiness across key global markets.
This success solidifies Elacestrant position as a high-impact systemic option for ER+/HER2– breast cancer and strengthens our leadership in a high-barrier, rapidly expanding SERD landscape. As growing global demand highlights the therapy’s rising market potential, this BE milestone brings significant commercial and strategic value to prospective partners.
On track for an early submission, unlocking a uniquely competitive advantage in the evolving endocrine therapy market.
U.S. Out-Licensing Opportunity Now Open
We invite U.S. commercialization partners to access a differentiated, oncology asset backed by robust science, regulatory momentum, and strategic timing aligned for high-value market entry.
For partnership discussions, please contact:
Maxim Vlasenko
Lead BD & Strategy, GlobalLux RX
